Welcome to our dedicated page for Heska news (Ticker: HSKA), a resource for investors and traders seeking the latest updates and insights on Heska stock.
Heska Corporation (NASDAQ: HSKA) delivers innovative veterinary diagnostic and imaging solutions to advance animal healthcare worldwide. This dedicated news hub provides investors and veterinary professionals with timely updates on Heska's strategic developments, technological breakthroughs, and market positioning.
Key Resources Include: Official announcements of new product releases, financial performance updates, partnership disclosures, and regulatory milestones. Track Heska's progress in diagnostic systems, imaging technologies, and allergy/renal health solutions through verified primary sources.
Stay Informed On: Earnings call details, acquisition activity, research collaborations like the Dalan Animal Health partnership, and enhancements to Heska's Cuattro imaging platform. This centralized repository eliminates the need to monitor multiple channels for critical updates.
Bookmark this page for efficient tracking of Heska's contributions to veterinary medicine and their impact on the animal health sector. Check regularly for unfiltered access to the company's latest advancements in pet care technology.
Heska Corporation (NASDAQ: HSKA) has announced an underwritten public offering of 940,860 shares of its common stock priced at $186.00 per share, totaling approximately $175 million in gross proceeds. The offering size was increased from $150 million to $175 million, with an option for underwriters to purchase an additional 141,129 shares. Proceeds will be used for general corporate purposes, including product development and potential acquisitions. The offering is expected to close on or around March 5, 2021.
Heska Corporation (NASDAQ: HSKA) has initiated an underwritten public offering of $150 million in common stock, with plans to provide underwriters a 30-day option for an additional 15% of shares sold. The funds will be used for general corporate purposes, including working capital, product development, and potential acquisitions, although no specific agreements are in place. The offering is subject to market conditions, and details will be filed with the SEC. J.P. Morgan and Piper Sandler & Co. are the joint book-running managers.
Heska Corporation (NASDAQ: HSKA) reported exceptionally strong financial results for Q4 and FY 2020. Consolidated revenue reached $64.3 million, up 90.5% year-over-year, and $197.3 million for the full year, a 60.9% increase. North America saw revenue grow by 29.3% in Q4 and 13.6% annually. The company successfully expanded its subscription services, achieving a 25% increase in active subscriptions in 2020. Despite challenges in international segments, overall gross margin remained resilient. Heska has set ambitious revenue guidance for 2021, forecasting $225-$235 million in consolidated revenue.
Heska Corporation (NASDAQ: HSKA), a leader in veterinary diagnostics, announced that CEO Kevin Wilson will present at several upcoming conferences in February and March 2021. Key events include the Bank of America Securities 2021 Virtual Animal Health Summit on February 25, Raymond James 42nd Annual Institutional Investors Conference on March 1, and Barclays Global Healthcare Conference on March 9. Each presentation will be accessible via webcast, and replays will be available for 90 days. Heska specializes in advanced veterinary diagnostic and specialty products.
Heska Corporation (NASDAQ: HSKA) will report its Q4 and full-year 2020 financial results on February 23, 2021, before market opening. An earnings call is scheduled for 9 a.m. MT / 11 a.m. ET to discuss the results. The call can be accessed via phone or through a live webcast on the company's investor relations website. A replay will be available after the call. Heska specializes in advanced veterinary diagnostic products across North America and internationally, providing various healthcare solutions.
Heska Corporation (NASDAQ: HSKA) announced its acquisition of Lacuna Diagnostics, a leader in point-of-care digital cytology technology and telemedicine. The deal, expected to close in Q1 2021, aims to enhance Heska's clinical specialty services, aligning with its goal to double product and revenue streams. Lacuna's innovative platform allows veterinarians to get rapid, expert analysis of diagnostic samples, improving care outcomes. This collaboration is poised to expand service reach and positively impact veterinary diagnostics.
Heska Corporation (NASDAQ: HSKA) has appointed Dr. Joachim Hasenmaier, former head of Boehringer Ingelheim Animal Health, to its Board of Directors effective January 11, 2021. Dr. Hasenmaier brings extensive experience in animal health, having overseen significant growth and acquisitions at Boehringer Ingelheim. His expertise is expected to enhance Heska's strategic execution and global positioning in the veterinary diagnostics market. CEO Kevin Wilson expressed enthusiasm, noting Hasenmaier's capability to foster innovation and growth while benefiting shareholders and the broader animal health industry.
Heska Corporation (NASDAQ: HSKA) announced that CEO Kevin Wilson will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 2 p.m. ET. Registered attendees can view the presentation live, while audio-only access is available for non-registered individuals. The session will include a Q&A segment. Additionally, Heska's management will hold one-on-one meetings on the same date, with contacts provided for meeting requests. Post-event, a webcast of the presentation will be archived on Heska's website for 90 days.
Heska Corporation (NASDAQ: HSKA) announced that President & CEO Kevin Wilson will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020. The presentation will be available for registered attendees from November 23 to December 3, with an archived replay on Heska's website for 90 days afterward. Alongside the presentation, Mr. Wilson will hold one-on-one meetings on the conference day, which can be arranged through Piper Sandler or Heska Investor Relations.
Heska Corporation (NASDAQ: HSKA) announced the appointment of Robert L. Antin, founder of VCA Antech, Inc., to its Board of Directors, effective November 17, 2020. Antin brings extensive experience in the veterinary healthcare sector, having served as CEO and Director of VCA since 1986. His leadership is expected to strengthen Heska's position in the competitive pet healthcare market. CEO Kevin Wilson expressed confidence in Antin's ability to drive growth and enhance shareholder value.
FAQ
What is the market cap of Heska (HSKA)?
